LU92172I2 - Solvat acétonique du cabazitaxel, ou désigné solvat acétonique du diméthoxy docetaxel ou solvat acétonique du (2R,3S)-3-tertbutoxycarbonylamino-2-hydroxy-3-phénylpropionate de 4-acetoxy-2a-benzoyloxy-5ß,20-époxy-1-hydroxy-7ß,10a-diméthoxy-9-oxo-tax-11-ène-13a-yle (acétonate du cabazitaxel) - Google Patents

Solvat acétonique du cabazitaxel, ou désigné solvat acétonique du diméthoxy docetaxel ou solvat acétonique du (2R,3S)-3-tertbutoxycarbonylamino-2-hydroxy-3-phénylpropionate de 4-acetoxy-2a-benzoyloxy-5ß,20-époxy-1-hydroxy-7ß,10a-diméthoxy-9-oxo-tax-11-ène-13a-yle (acétonate du cabazitaxel)

Info

Publication number
LU92172I2
LU92172I2 LU92172C LU92172C LU92172I2 LU 92172 I2 LU92172 I2 LU 92172I2 LU 92172 C LU92172 C LU 92172C LU 92172 C LU92172 C LU 92172C LU 92172 I2 LU92172 I2 LU 92172I2
Authority
LU
Luxembourg
Prior art keywords
cabazitaxel
hydroxy
dimethoxy
acetonic
solvate
Prior art date
Application number
LU92172C
Other languages
English (en)
French (fr)
Other versions
LU92172I9 (enExample
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34224354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92172(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of LU92172I2 publication Critical patent/LU92172I2/fr
Publication of LU92172I9 publication Critical patent/LU92172I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
LU92172C 2003-09-19 2013-03-20 Solvat acétonique du cabazitaxel, ou désigné solvat acétonique du diméthoxy docetaxel ou solvat acétonique du (2R,3S)-3-tertbutoxycarbonylamino-2-hydroxy-3-phénylpropionate de 4-acetoxy-2a-benzoyloxy-5ß,20-époxy-1-hydroxy-7ß,10a-diméthoxy-9-oxo-tax-11-ène-13a-yle (acétonate du cabazitaxel) LU92172I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0311016A FR2859996B1 (fr) 2003-09-19 2003-09-19 Solvat acetonique du dimethoxy docetaxel et son procede de preparation

Publications (2)

Publication Number Publication Date
LU92172I2 true LU92172I2 (fr) 2013-05-21
LU92172I9 LU92172I9 (enExample) 2019-01-03

Family

ID=34224354

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92172C LU92172I2 (fr) 2003-09-19 2013-03-20 Solvat acétonique du cabazitaxel, ou désigné solvat acétonique du diméthoxy docetaxel ou solvat acétonique du (2R,3S)-3-tertbutoxycarbonylamino-2-hydroxy-3-phénylpropionate de 4-acetoxy-2a-benzoyloxy-5ß,20-époxy-1-hydroxy-7ß,10a-diméthoxy-9-oxo-tax-11-ène-13a-yle (acétonate du cabazitaxel)

Country Status (37)

Country Link
US (1) US7241907B2 (enExample)
EP (1) EP1667986B1 (enExample)
JP (1) JP5010279B2 (enExample)
KR (1) KR101123588B1 (enExample)
CN (1) CN100429207C (enExample)
AR (1) AR045667A1 (enExample)
AU (1) AU2004274212B2 (enExample)
BE (1) BE2013C036I2 (enExample)
BR (1) BRPI0414492A8 (enExample)
CA (1) CA2539309A1 (enExample)
CR (1) CR8292A (enExample)
CY (2) CY1114575T1 (enExample)
DK (1) DK1667986T3 (enExample)
ES (1) ES2403149T4 (enExample)
FR (2) FR2859996B1 (enExample)
HR (1) HRP20130322T1 (enExample)
HU (1) HUS1300025I1 (enExample)
IL (1) IL174240A (enExample)
LU (1) LU92172I2 (enExample)
MA (1) MA28045A1 (enExample)
ME (2) ME00054B (enExample)
MX (1) MXPA06002639A (enExample)
MY (1) MY136668A (enExample)
NO (2) NO335997B1 (enExample)
NZ (1) NZ545835A (enExample)
PA (1) PA8612401A1 (enExample)
PE (1) PE20050870A1 (enExample)
PL (1) PL1667986T3 (enExample)
PT (1) PT1667986E (enExample)
RS (2) RS20060189A (enExample)
RU (1) RU2342373C2 (enExample)
SI (1) SI1667986T1 (enExample)
TN (1) TNSN06086A1 (enExample)
TW (1) TWI382022B (enExample)
UA (1) UA87115C2 (enExample)
WO (1) WO2005028462A1 (enExample)
ZA (1) ZA200602255B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080100264A (ko) * 2006-03-21 2008-11-14 닥터 레디스 레보러터리즈 리미티드 도세탁셀의 다형체와 그 제조방법
US7855591B2 (en) * 2006-06-07 2010-12-21 Atmel Corporation Method and system for providing a charge pump very low voltage applications
US7652522B2 (en) * 2006-09-05 2010-01-26 Atmel Corporation High efficiency low cost bi-directional charge pump circuit for very low voltage applications
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
FR2926551A1 (fr) * 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
AU2013205442B2 (en) * 2008-01-17 2016-05-12 Aventis Pharma S.A. Crystalline forms of dimethoxy docetaxel and methods for preparing same
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
FR2945211A1 (fr) * 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
AU2015200149B2 (en) * 2009-10-29 2016-12-01 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
CA2708489A1 (en) * 2009-10-29 2011-04-29 Aventis Pharma S.A. Use of cabazitaxel and a prednisone or a prednisolone in the treatment of prostate cancer
AU2010310986A1 (en) 2009-10-29 2012-06-14 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
CN103764637A (zh) * 2011-04-12 2014-04-30 普拉斯化学品有限公司 卡巴他赛的固态形式及其制备方法
WO2013024495A1 (en) * 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel
TWI526437B (zh) * 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
US8722900B2 (en) 2011-10-31 2014-05-13 Scinopharm Taiwan, Ltd. Process for cabazitaxel, and intermediates thereof
DE112012004569T5 (de) 2011-11-01 2014-08-14 Fresenius Kabi Oncology Ltd. Amorphe Form von Cabazitaxel und Verfahren zum Herstellen davon
PL2785701T3 (pl) 2011-11-28 2019-08-30 Fresenius Kabi Oncology Limited Krystaliczna postać kabazytakselu i sposób jej otrzymywania
EP2791122B1 (en) 2011-12-13 2019-01-23 Aventis Pharma S.A. Crystalline form of cabazitaxel and process for preparing the same
US9403785B2 (en) 2012-01-03 2016-08-02 Shilpa Medicare Limited Process for preparing amorphous cabazitaxel
WO2013117683A1 (en) * 2012-02-10 2013-08-15 Aventis Pharma S.A. New pediatric uses of cabazitaxel
US9394266B2 (en) 2012-03-08 2016-07-19 IVAX International GmbH Solid state forms of cabazitaxel and processes for preparation thereof
CN102675257B (zh) * 2012-05-10 2014-07-02 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法
CN102746258B (zh) 2012-07-25 2015-02-04 重庆泰濠制药有限公司 卡巴他赛的结晶形式及其制备方法
EP2880021A4 (en) 2012-07-31 2015-06-17 Yung Shin Pharm Ind Co Ltd AMORPHIC CABACITAXEL
EP2884963B1 (en) 2012-08-15 2017-12-27 Yung Shin Pharm. Ind. Co. Ltd. Stable pharmaceutical formulation of cabazitaxel
CN103664836B (zh) * 2012-09-20 2016-04-20 齐鲁制药有限公司 7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN103804323A (zh) * 2012-11-14 2014-05-21 上海希迈医药科技有限公司 一种卡巴他赛溶剂化物及其制备方法和应用
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法
EP2743264A1 (en) 2012-12-13 2014-06-18 INDENA S.p.A. New crystalline form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof
CN103910698B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛丙酮合物及其结晶
CN103910696B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛异丙醚合物及其结晶
EP2777691A1 (en) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
CN104277014A (zh) * 2013-07-04 2015-01-14 北京新天宇科技开发有限公司 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
WO2015000165A1 (zh) * 2013-07-04 2015-01-08 北京新天宇科技开发有限公司 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
EP2865674A1 (en) 2013-10-23 2015-04-29 INDENA S.p.A. Crystalline solvate forms of Cabazitaxel
EP2865675A1 (en) 2013-10-23 2015-04-29 INDENA S.p.A. A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof
CN103601704B (zh) * 2013-11-22 2015-05-06 石家庄智恒医药科技有限公司 无定形卡巴他赛的制备
WO2016113752A2 (en) 2015-01-12 2016-07-21 Emcure Pharmaceuticals Limited Liquid formulation of cabazitaxel
WO2016133387A1 (en) 2015-02-17 2016-08-25 Erasmus University Medical Center Rotterdam Use of cabazitaxel in the treatment of prostate cancer
EP3093014A1 (en) * 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンの薬学的に許容される塩
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
WO2020249507A1 (en) 2019-06-11 2020-12-17 Indena S.P.A. Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it
EP3808345A1 (en) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent
EP3797834A1 (en) 2019-09-25 2021-03-31 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
DE4425978C1 (de) * 1994-07-22 1995-11-23 Karlsruhe Forschzent Verfahren zur Herstellung keramischer Mikrostrukturen
MA23823A1 (fr) * 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2745814B1 (fr) * 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
EP0982027A1 (en) * 1998-08-17 2000-03-01 Aventis Pharma S.A. Taxoid derivatives for treating abnormal cell proliferation of the brain
US6346543B1 (en) * 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
US6136989A (en) * 1998-12-30 2000-10-24 Phytogen Life Sciences, Incorporated Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material
US5969165A (en) * 1999-01-07 1999-10-19 508037 (Nb) Inc. Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column
ATE256117T1 (de) * 1999-05-17 2003-12-15 Bristol Myers Squibb Co Neue umsetzungsbedingungen für die spaltung von silylethern bei der herstellung von paclitaxel (taxol(r)) und paclitaxel -analogen
ATE382624T1 (de) * 2001-11-29 2008-01-15 Daiichi Sankyo Co Ltd Kristalle von taxanderivaten und verfahren zu deren herstellung

Also Published As

Publication number Publication date
NZ545835A (en) 2009-10-30
NO2015013I2 (no) 2015-04-22
EP1667986A1 (fr) 2006-06-14
HK1093340A1 (zh) 2007-03-02
BE2013C036I2 (enExample) 2023-12-14
BRPI0414492A8 (pt) 2019-01-15
FR13C0037I2 (fr) 2015-11-20
RU2342373C2 (ru) 2008-12-27
CR8292A (es) 2008-10-15
AR045667A1 (es) 2005-11-02
ZA200602255B (en) 2007-07-25
RU2006113122A (ru) 2006-08-27
LU92172I9 (enExample) 2019-01-03
CA2539309A1 (fr) 2005-03-31
RS20060189A (sr) 2008-06-05
MXPA06002639A (es) 2006-06-05
FR2859996A1 (fr) 2005-03-25
IL174240A0 (en) 2006-08-01
KR20060072147A (ko) 2006-06-27
TNSN06086A1 (en) 2007-10-03
TWI382022B (zh) 2013-01-11
UA87115C2 (ru) 2009-06-25
US20050065138A1 (en) 2005-03-24
MY136668A (en) 2008-11-28
NO335997B1 (no) 2015-04-20
DK1667986T3 (da) 2013-05-06
TW200524891A (en) 2005-08-01
SI1667986T1 (sl) 2013-05-31
WO2005028462A1 (fr) 2005-03-31
MEP11708A (en) 2010-06-10
NO20061714L (no) 2006-04-19
PL1667986T3 (pl) 2013-06-28
RS54614B1 (sr) 2016-08-31
CN1849311A (zh) 2006-10-18
KR101123588B1 (ko) 2012-03-22
MA28045A1 (fr) 2006-07-03
AU2004274212A1 (en) 2005-03-31
PA8612401A1 (es) 2005-08-04
BRPI0414492A (pt) 2006-11-14
CN100429207C (zh) 2008-10-29
ME00054B (me) 2011-02-10
IL174240A (en) 2010-12-30
JP5010279B2 (ja) 2012-08-29
CY2013016I1 (el) 2018-01-10
US7241907B2 (en) 2007-07-10
CY1114575T1 (el) 2016-10-05
JP2007505866A (ja) 2007-03-15
FR2859996B1 (fr) 2006-02-03
ES2403149T4 (es) 2013-06-24
CY2013016I2 (el) 2018-01-10
PE20050870A1 (es) 2005-11-21
ES2403149T3 (es) 2013-05-14
HUS1300025I1 (hu) 2016-08-29
PT1667986E (pt) 2013-04-24
FR13C0037I1 (fr) 2013-09-08
AU2004274212B2 (en) 2010-03-04
EP1667986B1 (fr) 2013-01-16
HRP20130322T1 (en) 2013-07-31
NO2015013I1 (no) 2015-05-04

Similar Documents

Publication Publication Date Title
NO2015013I1 (no) Cabazitaxel acetonat, også betegnet acetonsolvat av cabazitaxel eller acetonsolvat av imetoksydocetaxel, eller acetonsolvat av 4-acetoksy-2¿-benzoyloksy-5ß,20-epoksy-1-hydroksy-ß,10ßdimetoksy-9-oksotaks-11-en-13¿-yl (2R,3S)-3-tertbutoksykarbonylamino-2-hydroksy-3-fenylpropionat
EP3856054A4 (en) BALLOON ENCAPSULATION AND ISOVOLUMETRIC ASPIRATION THROMBECTOMY CATHETER AND METHODS THEREOF
DE60131537D1 (de) Nitrosierte und nitrosylierte taxane, zubereitungen und methoden der verwendung
DE602004008105D1 (de) 42-o-alkoxyalkylrapamycinderivate und diese enthaltende zusammensetzungen
CY1119601T1 (el) Προαγωγεις αποπτωσης
DK1644348T3 (da) Epoxy-afsluttede polythioethere, Epoxy-afsluttede polythioethere
UY27598A1 (es) Composiciones farmacéuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada
ATE463264T1 (de) Absorbierende polymerzusammensetzungen, medizinische artikeln und verfahren
DK4346818T3 (da) Faste dosisformer og doseringsskemaer indeholdende (2r,3s,4s,5r)-4-[[3-(3,4-difluor-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl] amino]pyridin-2-carboxamid
EP1709152A4 (en) MOLECULAR SIGNATURE OF PTEN TUMOR SUPPRESSOR
EP4628033A4 (en) LIGHT OPENING INSTRUMENT, LIGHT OPENING SYSTEM AND LIGHT OPENING METHOD
ATE471937T1 (de) Cyclopropylgruppensubstituierte oxazolidinonantibiotika und derivate davon
CY1110449T1 (el) Συνδυασμος δοκεταξελης και φλαβοπιριδinολης
ATE431343T1 (de) Thio-analoga von paclitaxel und deren vorprodukte
DK1694660T3 (da) Fremgangsmåde til fremstilling af vandfri og hydrerede aktive farmaceutiske bestanddele (API's); stabile farmaceutiske sammensætninger fremstillet af disse og anvendelser af disse sammensætninger
ATE530547T1 (de) Derivate und analoge von chroman als funktionell selektive alpha2c-adrenorezeptor-agonisten
FR2860792B1 (fr) Derives de thiophene-2-carboxamide, leur preparation et leur application en therapeutique
WO2007076160A3 (en) C-10 carbamates of taxanes
ZA982093B (en) Dolastatin-15 derivatives in combination with taxanes.
WO2002078690A3 (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof
FR2862967B1 (fr) Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
DE50303394D1 (de) Ballontrokar
DE602004010667D1 (de) Zytotoxische depsipeptide
BR0201237A (pt) Processo de obtenção de lignanas dibenzilbutirolactÈnicas, processo de obtenção de derivados sintéticos de lignanas ostentando atividades quimioprofilática e terapêutica antichagásica
ATE401325T1 (de) C10-carbamoyloxysubstituierte taxane als antitumormittel